Latest News
The following news articles were published in 2022.
Ovarian carcinosarcoma as a distinct form of ovarian cancer
Our investigators report detailed clinical and histopathological characterisation of the largest pathologically confirmed cohort of ovarian carcinosarcoma patients to date: August 2022
New strategy to target cancer cells expressing PD-L1
Edinburgh researchers report a ligand-tetrazine conjugate approach to “track & treat” malignant cells that are capable of evading the immune system: August 2022
Drivers of endocrine therapy resistance in estrogen receptor positive breast cancer
Edinburgh researchers used a unique sample set to provide new insights into endocrine therapy resistance in estrogen receptor positive breast cancer: August 2022
Increased incidence of Type 1 diabetes during the COVID-19 pandemic is not a direct effect of recent COVID-19 infection
A recent publication in the journal Diabetes Care from Professor Helen Colhoun and Professor Paul McKeigue's groups, reports that although the incidence of type 1 diabetes rose sharply among young persons during the early part of the COVID-19 pandemic that this was not a direct effect of COVID-19 infection itself. July 2022
Liz Patton Research Group receives award to track melanoma
The award, from Melanoma Research Alliance, will support a recent technology called "barcoding" which aims to help advance therapies in melanoma patients: July 2022
Blood test could predict future risk of leukaemia
The collaborative study between the Universities of Edinburgh and Glasgow was co-lead by the Tamir Chandra Research Group and involved work by two Research Fellows from the Cross-Disciplinary Fellowships (XDF) Programme: July 2022.
Multiomic characterization of high-grade serous ovarian carcinoma enables high-resolution patient stratification
Edinburgh led study provides high-resolution picture of the molecular landscape in high-grade serous ovarian carcinoma, better defining patients who may benefit most from specific molecular therapeutics and highlighting those for whom novel treatment strategies are needed to improve outcomes: July 2022
X-Net launches to remove obstacles to cross-disciplinary research careers
The Medical Research Council has invested £200,000 in a new national network which will help scientists overcome barriers to working in interdisciplinary science: July 2022
A new tool for rapid protein degradation in live animals
Andrew Wood and colleagues develop new tool for modulating protein levels in vivo: June 2022
Characterisation of a nucleo-adhesome
A study by Edinburgh scientists provides important new information on the ability of cell adhesion molecules to relocate to the cell nucleus: June 2022
Professor Cathy Abbott elected as BNA Trustee of Research Policy
Professor Cathy Abbott has been elected as Trustee of Research Policy on the British Neuroscience Association (BNA) Council
Professor David Porteous retires
University of Edinburgh colleagues wish Professor David Porteous well for his retirement after four decades of research: April 2022
£22 million investment launches MRC National Mouse Genetics Network
Key members of Network clusters include Institute scientists Ian Tomlinson (Cancer), Andrew Wood, Joe Marsh, Asier Unciti-Broceta (Degron Tagging) and Pleasantine Mill, (Congenital Anomalies): April 2022
Tom Deegan receives Early Career Research Award
Tom’s work and contribution as an exceptional early career researcher has been acknowledged in the Biochemical Society’s annual awards: April 2022
Early Career Prize for Didier Devaurs
Cross-disciplinary Fellow Didier Devaurs has received a SULSA award for his work using cutting-edge machine learning techniques to resolve challenges with deep mutational scanning: March 2022
COVID-19 testing: disparity between national and institution-based case detection
TestEd data suggests that public health messaging should acknowledge that reduced testing and under-reporting of positive Lateral Flow Tests could under-estimate community prevalence: March 2022
Loss of Integrin-Linked Kinase sensitizes breast cancer to SRC inhibitors
Our researchers demonstrated that loss of Integrin-Linked Kinase sensitizes triple negative breast cancer to SRC inhibition: February 2022
New understanding of mutation pattern holds potential for more tailored cancer treatment
A team of researchers from the MRC Human Genetics Unit have found that the enzyme TOP1 is an important source of mutations in active genes: February 2022
Ovarian cancer therapy boosted by drug that slows disease’s advance
Trametinib, currently used to treat skin and lung cancers, has been found to slow the progression of a form of ovarian cancer and increase the number of patients who respond to treatment, a clinical trial has found: February 2022
Scientists in Scotland to get £12 million boost from Cancer Research UK
The charity has announced that experts in Edinburgh and Glasgow - the Cancer Research UK Scotland Centre - will receive the funding over the next five years for their ground-breaking work as part of a unique chain of cutting-edge research hubs around the UK: February 2022
Blood proteins could be the key to a long and healthy life, study finds
Research from the Jim Wilson Research Group suggests two blood proteins influence how long and healthy a life we live: January 2022
Live from the Lab with the Brain Tumour Award team
Virtual Lab Tour with Prof Neil Carragher’s Research Group
Tech spinout aims to ‘democratise data’ to boost medical research
Scientists at the MRC Human Genetics Unit and Roslin Institute have launched a spinout company that aims to democratise genetic data access and cut from days to minutes the time it takes to analyse millions of genetic records: January 2022
Zebrafish study unlocks understanding of developmental mechanisms hijacked in cancer
The work, led by Alessandro Brombin and Liz Patton and in collaboration with Tamir Chandra, could potentially inform improved drug therapies for people living with melanoma: January 2022
Disparities in breast cancer care quality have reduced
Regional variation in chemotherapy treatment for breast cancer across Scotland has reduced significantly over the past 15 years, according to a new study: December 2021
TestEd team awarded Principal’s Medal at winter graduation ceremony
Professor Tim Aitman received the medal on behalf of the team for significant achievements in pioneering a way to mass population testing in an epidemic: December 2021
Multi-omic machine learning predictor of breast cancer therapy response
Edinburgh clinicians contributed to a study that developed new AI-based predictor of response to cancer therapy: December 2021